biosimilars

Patients

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

R&D

At Reuters Pharma Europe, Sandoz' Claire D'Abreu-Hayling explored the promise of the so-called “golden decade” of patent expiry for generics.

News

After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.

News

The FDA has issued additional guidance that aims to make it easier for drugmakers to bring biosimilars of patent-expired biologic drugs to market.

News

India's Sun Pharma has downplayed a rumour that it is in talks to acquire women's health specialist and MSD spinout Organon for $10bn.

News

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.